Masahiro Hatooka

发表

Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large‐scale, long‐term cohort study

M. Imamura, K. Chayama, D. Miki, 2016, Journal of gastroenterology and hepatology.

Preoperative Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Prediction of Microvascular Invasion in Small Hepatocellular Carcinoma

K. Awai, M. Imamura, K. Chayama, 2016, Journal of computer assisted tomography.

Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus‐related cirrhosis

M. Imamura, K. Chayama, D. Miki, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Improvement of renal dysfunction in a patient with hepatitis C virus‐related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report

M. Imamura, N. Hiraga, K. Chayama, 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy

M. Imamura, K. Chayama, D. Miki, 2017, PloS one.

Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis

M. Imamura, K. Chayama, H. Aikata, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease

M. Imamura, K. Chayama, H. Aikata, 2017, Journal of Gastroenterology.

Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg‐interferon, and ribavirin combination treatment for chronic hepatitis C

M. Imamura, N. Hiraga, K. Chayama, 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib

M. Imamura, K. Chayama, H. Aikata, 2017, Oncology.

Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma

M. Imamura, K. Chayama, H. Kohno, 2015, Journal of digestive diseases.

Clinical outcome and prognostic factors in hepatocellular carcinoma patients with bone metastases medicated with zoledronic acid

M. Imamura, K. Chayama, H. Aikata, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

[A case report of hepatocellular carcinoma with metastases to the lip, stomach, and colorectum].

K. Chayama, H. Aikata, M. Kaneko, 2014, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: Comparison with primary cases.

M. Imamura, K. Chayama, H. Aikata, 2015, European journal of radiology.

Early experience of seven hepatocellular carcinoma cases treated with regorafenib

M. Imamura, K. Chayama, H. Aikata, 2018, Clinical case reports.

Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real‐world practice

M. Imamura, K. Chayama, H. Aikata, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Comparison of hepatic arterial infusion chemotherapy between 5‐fluorouracil‐based continuous infusion chemotherapy and low‐dose cisplatin monotherapy for advanced hepatocellular carcinoma

K. Awai, M. Imamura, K. Chayama, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis

M. Imamura, K. Chayama, T. Kimura, 2018, Oncology.

Advanced liver fibrosis effects on the response to sofosbuvir‐based antiviral therapies for chronic hepatitis C

M. Imamura, K. Chayama, D. Miki, 2018, Journal of medical virology.

Complete response to short‐term sorafenib treatment alone for hepatocellular carcinoma with bone, lymph node, and peritoneum metastases

M. Imamura, K. Chayama, H. Aikata, 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

Assessment of Outcome of Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma by the Combination of RECIST and Tumor Markers.

K. Awai, M. Imamura, K. Chayama, 2016, Hiroshima journal of medical sciences.

Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status

M. Imamura, K. Chayama, H. Kohno, 2018, Journal of gastroenterology and hepatology.

造影超音波にて特徴的な腫瘍内貫通血管を認めた肝Mucosa associated lymphoid tissueリンパ腫の一例

M. Imamura, K. Chayama, K. Arihiro, 2017 .

Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection

M. Imamura, K. Chayama, K. Arihiro, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma

M. Imamura, K. Chayama, T. Kimura, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.

M. Imamura, K. Chayama, H. Kohno, 2016, Anticancer research.

Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial

K. Awai, M. Imamura, K. Chayama, 2018, BMC Cancer.